![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC13A3 |
Gene summary for SLC13A3 |
![]() |
Gene information | Species | Human | Gene symbol | SLC13A3 | Gene ID | 64849 |
Gene name | solute carrier family 13 member 3 | |
Gene Alias | ARLIAK | |
Cytomap | 20q13.12 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q8WWT9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64849 | SLC13A3 | HCC1_Meng | Human | Liver | HCC | 2.54e-02 | -2.93e-02 | 0.0246 |
64849 | SLC13A3 | HCC1 | Human | Liver | HCC | 5.89e-22 | 4.50e+00 | 0.5336 |
64849 | SLC13A3 | S014 | Human | Liver | HCC | 7.28e-55 | 2.24e+00 | 0.2254 |
64849 | SLC13A3 | S015 | Human | Liver | HCC | 3.53e-61 | 2.92e+00 | 0.2375 |
64849 | SLC13A3 | S016 | Human | Liver | HCC | 7.07e-61 | 2.13e+00 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:015010411 | Liver | HCC | transport across blood-brain barrier | 50/7958 | 87/18723 | 3.42e-03 | 1.55e-02 | 50 |
GO:001023211 | Liver | HCC | vascular transport | 50/7958 | 88/18723 | 4.69e-03 | 2.02e-02 | 50 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC13A3 | SNV | Missense_Mutation | rs752308476 | c.1130N>A | p.Ser377Tyr | p.S377Y | Q8WWT9 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SLC13A3 | SNV | Missense_Mutation | rs779839556 | c.1480N>T | p.Val494Phe | p.V494F | Q8WWT9 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A8-A082-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
SLC13A3 | SNV | Missense_Mutation | rs201877988 | c.1757N>G | p.Asn586Ser | p.N586S | Q8WWT9 | protein_coding | tolerated(0.06) | benign(0.178) | TCGA-A8-A09K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC13A3 | SNV | Missense_Mutation | rs779839556 | c.1480N>T | p.Val494Phe | p.V494F | Q8WWT9 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
SLC13A3 | SNV | Missense_Mutation | c.1276N>T | p.Pro426Ser | p.P426S | Q8WWT9 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
SLC13A3 | SNV | Missense_Mutation | c.1741N>A | p.Asp581Asn | p.D581N | Q8WWT9 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
SLC13A3 | SNV | Missense_Mutation | c.550N>G | p.Arg184Gly | p.R184G | Q8WWT9 | protein_coding | tolerated(0.25) | benign(0.005) | TCGA-D8-A1XF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
SLC13A3 | insertion | Nonsense_Mutation | novel | c.1785_1786insTAGAT | p.Asn596Ter | p.N596* | Q8WWT9 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SLC13A3 | SNV | Missense_Mutation | novel | c.1164N>G | p.Ile388Met | p.I388M | Q8WWT9 | protein_coding | deleterious(0.03) | benign(0.209) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
SLC13A3 | SNV | Missense_Mutation | rs767074268 | c.985N>T | p.Arg329Trp | p.R329W | Q8WWT9 | protein_coding | deleterious(0.05) | possibly_damaging(0.806) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |